Abstract
Five healthy volunteers received a single oral dose of amylobarbitone sodium (200 mg) and placebo in a double blind randomized fashion. Peak velocity of horizontal saccadic eye movements, saccade duration and smooth pursuit velocity were measured at intervals up to 6 h after drug administration. The active treatment produced a statistically significant decrease of both saccadic and smooth pursuit eye velocity. The maximum effect was observed 2 h after drug administration. The effect on peak saccadic velocity was still statistically significant 6 h after treatment. The maximum impairment in eye movement performance ranged between 25 and 29%. These results demonstrate that both saccadic and smooth pursuit systems are unable to generate the required eye velocity under the influence of a therapeutic dose of amylobarbitone sodium.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
